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Bispecific antibodies are regarded as efficient tools for the
immunological treatment of disseminated tumour cells in minimal
residual disease situations. Usually, they are constructed to target
tumour cells by a specific or tumour-associated antigen and to
recruit one class of immune effector cell, either T cells or acces-
sory cells like monocytes or natural killer cells. However, long-
lasting immune reactions in vivo are much more complex and
depend on the activation of different classes of immune effector
cells, especially in the initial phase of the immune response. This
is usually regarded as the major drawback of conventional bsAb
that may not yield full immune responses at the tumour site. We
have developed a new class of bispecific antibody, that is
composed of the two potent subclasses mouse IgG2a ´ rat IgG2b.
BiUII, a member of these new bispecific molecules, targets
tumour cells via the pan-carcinoma antigen EpCAM and
T-lymphocytes via CD3. But, in contrast to other bispecific
molecules described to date (Fanger et al, 1990; Valerius et al,
1997; Weiner et al, 1995), it also binds and activates human Fcg-
receptor-positive accessory cells like monocytes/macrophages,
NK cells, and dendritic cells (DCs) via its Fc-region. Activation of
these accessory cells results in the upregulation of costimulatory
molecules like CD40, CD80, and CD86 and the production of
cytokines like IL-2, IL-6, and DC-CK1 (Zeidler et al, 1999).
Although T cells are considered to be the most important cells
for tumour cell elimination, they depend on proper antigen presen-
tation by professional antigen-presenting cells (APCs) or activated
accessory cells and costimulatory molecules like CD40, LFA-3,
CD80, and CD86 in the presence of cytokines such as IL-2 and IL-
12 (Inaba and Steinman, 1984; Stüber et al, 1996). This reveals the
importance of the subclass combination for induction of activation
signals via the Fc-receptor of accessory cells. A similar T-cell
redirecting bsAb, SHR-1 (anti-CD3 ´ anti-CD19), with the
subclass combination mouse IgG1 ´ rat IgG2b was neither able to
activate accessory cells via its Fc-region in a clinical study (de
Gast et al, 1995) nor in in vitro assays without addition of exoge-
nous IL-2 (Klein et al, 1997). Moreover, the antitumour efficiency
of BiUII is strongly reduced when T cells alone are used as
effector cells. We therefore postulate that only the activation of
more than one class of immune effector cell is necessary to
provide optimal antitumour efficiency. Furthermore, phagocytosis,
processing, and presentation of tumour material by APCs are
prerequisites for the induction of a polyclonal humoral and cellular
antitumour immune response. These data are in accordance with
the work of Clynes et al (1998), who recently demonstrated the
importance of Fc receptors in passive and active immunity to a
melanoma model.
MATERIALS AND METHODS
Cell lines and PBMC preparation
PCl-I (a gift from Dr T Whiteside, Pittsburgh, PA, USA) is an
adherent squamous carcinoma cell-line of the head and neck
(SCCHN) and is kept in DMEM with 10% FCS. The cell-line
expresses EpCAM but lacks CD80 and CD86 as tested by flow
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(PBMC) were isolated from heparinized blood of voluntary donors
by Ficoll density centrifugation.
Monoclonal antibodies
mAbs for FACS analysis were from Pharmingen (Hamburg,
Germany) except the DC-specific antibody BMA-X11 (Dianova,
Hamburg, Germany).
Generation of dendritic cells
The adherent fraction of PBMCs was incubated for 7 days in
Iscove’s medium with 5% FCS (both Gibco BRL, Gaithersburg,
MD, USA) and 800 U ml–1 each of human IL-4 and GM-CSF
(both Boehringer Mannheim, Penzberg, Germany).
FACS® analysis
For FACS® analysis, 105 cells were incubated with the primary
antibody for 30 min on ice in PBS with 2% FCS. Cells were
washed twice in PBS and incubated for another 30 min with the
second, FITC-labelled, antibody. After two final washings, propid-
iumiodide was added and flow cytometry was performed using a
FACSCalibur® cytometer and the CellQuest analysis program
(Becton Dickinson, Heidelberg, Germany). For isolation of highly
purified CD2+ cells, PBMCs were incubated with FITC-labeled
antibodies and separated on a FACS-Calibur
®.
Production of BiUIl
The BiUII Quadroma was produced as previously described
(Lindhofer et al, 1995). The following hybridomas have been
used: 26ll6 (rat IgG2b, anti-CD3, provided by R Schuh, GSF,
Germany) and C215 (mouse IgG2a, anti-EpCAM, kindly provided
by M Dohlsten, Pharmacia Upjohn, Sweden). To isolate hybrid Ab
molecules of the subclass combination rat IgG2b/mouse IgG2a
from quadroma, the supernatants were centrifuged, filtered, and
loaded onto a 5 ml Econo Pac protein A column (Biorad,
Richmond, CA, USA). After washing with 10 volumes of PBS,
antibodies with the hybrid heavy-chain configuration were eluted
with 0.1 M citric acid, pH 5.1.
Cell culture and killing efficiency
For determination of BiUII-mediated killing of tumour cells and
cytokine production, 1 ´ 104 PCl-1 cells per well (targets = T)
were pipetted in 96-well flat-bottom plates (Falcon) and PBMCs
or subpopulations of these effectors (= E) were added at E:T ratios
from 40:1 to 1:1. BiUII was used at 10 ng per well in a total
volume of 100 ml per well RPMI with 10% FCS. Plates were incu-
bated for 3 days at 37°C in a humified atmosphere and 5% CO2.
Isolation of monocytes/macrophages and NK cells
CD14+ monocytes/macrophages and CD56+/CD3– NK cells were
isolated from PBMCs using PE-labelled monoclonal antibodies
and a Becton Dickinson FACSVantage cell sorter. Purity of
isolated cells was examined by flow cytometry.
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Figure 1 Binding of BiUIl to PBMC subpopulations. PBMCs were incubated
with BiUIl and binding was assessed by FACS analysis. (A) BiUIl recognizes,
albeit weakly, CD14+ monocytes (black line). As monocytes do not express
CD3, binding of BiUIl is probably mediated by the Fc-region that binds to
FcgRI with high affinity. (B) BiUIl strongly binds to CD3-expressing
CD4+/CD8+ T lymphocytes. (C) No binding of BiUIl antibodies was observed
on CD19+ B cells. Isotype control = dotted line.FITC-labelling and uptake of PCl-1 tumour cells
PCl-1 cells were washed twice with Ca2+ and Mg2+ free PBS. 1 ml
of FITC (1 mg ml–1 in Ethanol; Sigma, Deisenhofen, Germany)
was then added to each 2 ´ 105 tumour cells in 100 ml PBS, and
cells were shaken for 30 min at room temperature. Thereafter,
FITC-labelled PCI-1 cells were washed twice with cell culture
medium and added to PBMC cultures. The intensity of FITC-
labeling was monitored by FACS analysis. Phagocytic capacity of
PBMC co-incubated with FITC-labelled PCl-1 cells and BiUII
was revealed by FACS after staining with PE-labelled mouse-anti-
human-CD14 or –CD19 antibodies. FITC fluorescence intensity of
vital CD14+ or CD19+ PBMCs was measured and interpreted as
uptake of FITC-labelled PCl-1 tumour cells. Binding of BiUII to
PBMC subclasses was revealed by FACS analysis after double-
staining with FITC-labelled mouse-anti-rat antibodies (Dianova,
Hamburg, Germany) and PE-labelled mouse-anti-
human–CD4/CD8, –CD14, or –CD19 antibodies. A combination
of gates (vital cells, CD14+ or CD19+ and FCS vs SSC) was used
to exclude aggregates of PCl-1 cells with PBMCs from our
analysis of phagocytosis of tumour cells.
MTT-Assay
To assess BiUII-mediated tumour cell killing, a colourimetric
MTT-based assay was performed as previously described (Heo et
al, 1990). Briefly, PCI-1 target cells were plated in wells of a 96-
well flat-bottom plate and incubated overnight to prepare semicon-
fluent cell monolayers. Effector cells were added to the tumour
cell monolayers at the appropriate ratios and plates were incubated
for 24–48 h. After removing effectors by washing, MTT solution
(0.5 mg ml–1; Sigma) was added, and plates were incubated for a
further 4 h. The MTT solution was removed and blue crystals of
formazan formed in viable tumour cells were dissolved by adding
dimethylsulphoxide. Plates were read at 540 nm in a spectropho-
tometer and results were calculated based on the mean absorbance
obtained from at least six wells according to the following
formula: % cell death = 100 ´ (C–E)/(C–B), where C is the optical
density reading of the cells with target cells in the absence of effec-
tors (control), B is background without any cell population, and E
is the optical density reading of adherent tumour cells remaining in
the well after co-incubation with effector cells.
Activity of GTP cyclohydrolase I and cellular pterin
levels
The activity of GTP cyclohydrolase I was determined in the super-
natant fraction of the cell extracts (Tris/HCl, pH 8.0; 2.5 mM
EDTA) after acidic iodine oxidation of the reaction product dihy-
droneopterin triphosphate. The neopterin phosphates were sepa-
rated by ionpairing HPLC and fluorometrically detected. Cellular
neopterin and biopterin were determined in aliquots of the cell
extracts after acidic iodine oxidation, deproteinization by
trichloroacetic acid, pre-purification by cation-exchange chro-
matography and separation by reverse-phase HPLC, basically as
described previously (Kerler et al, 1990).
RESULTS
BiUIl binds to CD3–, FcgR+ accessory cells
We constructed a new class of bispecific antibody, BiUII, that
recognizes epithelial tumour cells via the pan-carcinoma antigen
EpCAM (Quak et al, 1990) and redirects T lymphocytes via CD3.
We have recently shown that BiUII displays an excellent antitu-
mour activity and also that complete PBMCs are superior to a
highly purified T-cell population of the same donor with regard to
tumour cell killing (Zeidler et al, 1999). We therefore addressed
the question whether BiUIl binds peripheral blood monocytes
which express the high-affinity Fcg-RI, CD64 and whether these
accessory cells contribute to tumour cell killing. To this end,
PBMCs were incubated with BiUII and a FITC-labelled anti-rat lg
antibody and binding was assessed by FACS analysis. As depicted
in Figure 1, BiUII binds to CD14+, albeit weakly. Since neither
antigen recognized by BiUIl (CD3 and EpCAM) is present on
monocytes, we concluded that binding of BiUIl to Fcg-R-positive
accessory cells is most probably mediated by the Fc region of
BiUIl. This finding is in agreement with data already published
(Haagen et al, 1995). In parallel, we investigated the binding of
BiUIl to T and B lymphocytes. T lymphocytes express CD3, one
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Figure 2 BiUIl stimulates accessory cells to phagocytose PCl tumour cells.
FITC-labelled PCl cells were cocultivated with PBMCs for 15 h with or without
BiUIl. After 15 h, monocytes (CD14+) and B cells (CD19+) were analysed for
the presence of FITC, indicating the phagocytosis of PCl cells. (A) The most
prominent FITC mean values (248) were observed in monocytes incubated in
the presence of BiUIl. A much lower intensity (76) was observed where BiUIl
was omitted. Background value of PBMC was 9. Similar results were
observed after 24 or 48 h cocultivation period (data not shown). (B) In
contrast, no FITC was incorporated in B cells.target molecule for BiUIl, and consequently a strong binding was
observed. In contrast, BiUIl does not bind to CD19+ B cells that
only express the low-affinity FcgRII, CD32.
BiUIl-mediated phagocytosis of PCl-1 cells by CD14+
monocytes/macrophages
Since accessory cells contribute to T-cell activation and tumour-
cell elimination in different ways, we wanted to find out whether
direct phagocytosis of the tumour cells by CD14+ cells occurs. To
this end, PCI-1 tumour cells were stained with FITC and coculti-
vated for 15 h with PBMCs in the presence of BiUII to assess
direct phagocytosis of tumour cells. In control settings, BiUII
and/or FITC-labelled tumour cells were omitted. After concultiva-
tion, the mean FITC-fluorescence intensity, indicative for the
uptake of labeled PCI-1 cells, was measured in vital CD14+
monocytes or CD19+ B lymphocytes. As shown in Figure 2A,
uptake of FITC-fluorescence was triggered in CD14+ mono-
cytes/macrophages co-cultivated with BiUII. In contrast, CD19+
B cells from the same donor showed no signs for PCI-1 uptake,
even in the presence of the bispecific molecule (Fig. 2B).
BiUIl stimulates the production of neopterin and
biopterin
Stimulation of T cells causes release of interferon-g, which in turn
induces increased expression of GTP cyclohydrolase I in mono-
cytes/macrophages and in the T cells themselves (Schott et al,
1993; Ziegler, 1990). This enzyme initiates and controls the
biopterin synthesis pathway. Therefore, activated T cells produce
tetrahydrobiopterin, whereas monocytes/macrophages cannot
complete the pathway. They terminate the synthesis pathway after
the first step and instead accumulate and shed neopterin. Increase
in the activity of GTP cyclohydrolase I and the synthesis of
neopterin and biopterin are therefore indicators of
monocyte/macrophage and of T-cell activation, respectively
(Ziegler, 1990). Figure 3 demonstrates that BiUII induces GTP
cyclohydrolase activity and enhancement of neopterin and
biopterin production in PBMC after cocultivation with tumour
cells in the presence of BiUII, indicative for activation of T cells
and monocytes.
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Figure 3 BiUIl induces GTP-cyclohydrolase I activity and the production of
neopterin and biopterin in monocytes/macrophages. PCl-1 cells were
cocultivated with PBMCs either with (100 ng ml–1) or without BiUIl for 2 days.
(A) The production of neopterin and biopterin and (B) the activity of GTP
cyclohydrolase was determined. BiUIl stimulates the production of both
biopterin and the monocyte-specific neopterin, as well as the activity of the
enzyme. PCl-1 cells per se are negative for all three products.
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Figure 4 BiUIl binds to NK cells. Binding of BiUIl to highly purified,
CD16+/CD3-NK cells from peripheral blood was investigated by FACS. Mean
values are 64 with (black line) and 24 without BiUIl (grey trace).
Figure 6 NK cells are stimulated to kill allogeneic tumour cells after
incubation with BiUIl. Highly purified CD56+CD32NK cells (effectors) were
cocultivated with PCl-1 cells at different E/T ratios for 2 days either with
(100 ng ml–1) or without BiUIl. Killing of tumour cells (targets) was calculated
in a MTT assay as described in Material and methods. One representative of
three independent experiments is shown.
Figure 5 Addition of BiUIl to a culture of purified NK cells induces the
expression of CD95, an activation marker for NK cells after 1 day of culture.
Mean values are 400 (black line) and 182 (grey trace) for NK cells incubated
with and without BiUIl, respectively.
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NK cells are known to play a pivotal role for the elimination of
tumour cells. Since NK cells express the low-affinity FcgRIII
(CD16), we wondered whether BiUIl not only binds to CD64+
monocytes/macrophages but also to CD16+ NK cells. We there-
fore isolated highly purified CD56+/CD3– NK cells and incubated
them with BiUIl and revealed binding of the bispecific antibody by
FACS analysis (Figure 4).
Binding of BiUII to NK cells via CD16 should lead to their acti-
vation, resulting in an antitumour activity. We therefore looked for
BiUII-mediated induction of CD95 on NK cells, which is recog-
nized as an activation marker for these cells (Medvedev et al,
1997; Robertson et al, 1995) and investigated tumour-cell killing
by BiUII-activated NK cells. As shown in Figure 5, addition of
BiUIl to the cell culture induces the expression of CD95 on
CD3–/CD16+NK cells indicating their activation via the Fc-region
of BiUII. Consequently, cocultivation of NK cells with allogeneic
PCI-1 tumour cells in the presence of BiUII resulted in enhanced
tumour-cell killing (Figure 6). We observed that NK cells per se
display a remarkable activity against allogeneic cells. However,
this cytotoxicity was further enhanced by the addition of BiUII.
BiUIl induces the upregulation of costimulatory
molecules on dendritic cells
The network of dendritic cells (DCs) is another class of key regu-
lators of immune responses. DCs are potent antigen-presenting
cells (Steinman, 1991) and trigger the activation of T cells, e.g. via
the CD40-dependent pathway (McLellan et al, 1996). Activation
of DCs is characterized by the neoexpression of CD83 (Czerniecki
et al, 1997; Zhou and Tedder, 1996) and upregulation of costimu-
latory molecules (Cella et al, 1996). Thus, DCs are thought to be
involved in the generation of cytotoxic T cells (Cella et al, 1996;
Ridge et al, 1998).
The objective of this study was to investigate whether DCs are
activated by BiUIl. DCs were generated from the adherent fraction
of PBMCs by incubating these cells for 2 weeks in the presence of
IL-4 and GM-CSF. The percentage of DCs in the culture was
checked by staining with the DC-specific antibody BMA-X11 and
was shown to be > 80% (not shown). The DCs were incubated
overnight either with BiUII (100 ng ml–1) or left untreated in cell
culture medium only. After 16 h, the expression of surface markers
CD83 and CD86 was revealed by FACS analysis. As shown in
Figure 7, incubation of DCs in the presence of BiUII leads to the
upregulation of both CD83 and the costimulatory signal CD86,
indicating the activation of DCs mediated by our bispecific
molecule.
DISCUSSION
We demonstrate here that not only the two specific binding arms
but also the Fc-region of a bispecific antibody can contribute to
activation of immune effector cells and thus to anti-tumour
activity. However, binding of Fcg receptors and activation of Fcg-
R expressing cells strictly depends on the composition of the Fc-
region of the bispecific molecule. Mouse IgG2a and rat IgG2b are
two evolutionally related potent effector subclasses that, in combi-
nation, exert efficient activation of human accessory cells. This is
shown by:
• the upregulation of costimulatory molecules and activation
markers like CD83, CD86, and CD95
• the upregulation of neopterin synthesis
• the direct phagocytosis of tumour cells by purified monocytes,
and
• the direct killing by isolated accessory cells without the
contribution of T cells.
Interestingly, PBMCs were only weakly activated by equimolar
amounts of the two parental monoclonal antibodies (Zeidler et al,
1999).
Conventional bsAbs are usually composed of one potent
subclass like mouse IgG2a or rat IgG2b and a less potent subclass
like mouse 1gG1 (de Gast et al, 1995), or even two less potent
subclasses (Weiner et al, 1993). As a consequence, the Fc-region
of conventional bsAbs is usually not able to activate human acces-
sory cells. Instead, these bispecific molecules bind and activate a
single class of effector cell via one of their binding arms. This has
the drawback that, in the case of T cells, an isolated activation via
the CD3 molecule without appropriate costimulatory signals may
cause activation-induced anergy (Daniel et al, 1998). We therefore
constructed a bispecific antibody that activates more than one class
of immune cell, a situation that much more resembles inflamma-
tory and immune reactions in vivo. We have already shown the
potential of such new bsAbs in tumour eradication in an animal
Activation of accessory cells by Bi UII 265
British Journal of Cancer (2000) 83(2), 261–266 © 2000 Cancer Research Campaign
Figure 7 Induction of CD83 and CD86 on dendritic cells. Addition of BiUIl
for 1 day to a culture of DCs leads to upregulation of (A) the activation
marker CD83 (B) and the costimulatory molecule CD86. Only cells positive
for the DC marker BMA-X11 were considered for analysis. With BiUIl = black
line; without antibody = grey trace.
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Bmodel (Lindhofer et al, 1996). The aim of the experiments
presented here was to reveal the mechanisms that are induced
by this new agent, in more detail. Therefore, we demonstrate the
activation of accessory cells that either express Fcg-RI (mono-
cytes/macrophages and DCs) or Fcg-RIII (NK cells). We also
show that, for example, monocytes/macrophages not only are acti-
vated but also directly contribute to the anti-tumour activity of
BiUII by phagocytosis. In contrast, this mouse IgG2a ´ rat IgG2b
bispecific molecule does not bind to B lymphocytes that express
the low-affinity receptor CD32. Enhanced production of tetrahy-
drobiopterin after BiUII stimulation may also participate in the
modulation of cell functions, e.g. by increasing NO production
(Mayer and Hemmens, 1997). Further, accessory cells deliver
molecules like CD40, CD80, and CD86, important for T-cell acti-
vation (McLellan et al, 1996; Van Gool et al, 1996) and produce
pro-inflammatory cytokines (Zeidler et al, 1999). The significance
of accessory-cell activation is underlined by data recently
published that demonstrates the importance of CD28 costimula-
tion for the prevention of activation-induced T-cell death in an
bsAb-immunotherapy trial (Daniel et al, 1998).
Probably most important, due to the recruitment of different
immune effector cells, BiUII-mediated immune complexes repre-
sent a self-supporting system that is not dependent on the addition
of exogenous IL-2, a fact that is extremely advantageous for
in vivo applications. The concerted activation of T cells and
accessory cells at the tumour site, leading to the phagocytosis,
processing, and presentation of tumour material, may account for
the potential of this new class of intact bispecific antibody and is a
prerequisite for a polyclonal humoral and cellular immune
response. Although HAMA or HARA reactions in vivo cannot be
excluded, especially after repeated applications, this new class of
bispecific molecule may represent a promising tool for the
adjuvant treatment of cancer patients.
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